Li, Grace

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 175

Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network

Li, G., Bielicki, J. A., Ahmed, A. S. M. N. U., Islam, M. S., Berezin, E. N., Gallacci, C. B., Guinsburg, R., da Silva Figueiredo, C. E., Santarone Vieira, R., Silva, A. R., et al. (2020) · Archives of Disease in Childhood

Neonatal and Maternal InfectionsAntibiotic Use and Resistance

Cited by 106

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky, N. G., Li, G., Aley, P., Costa Clemens, S. A., Barrett, J. R., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E., Dold, C., Felle, S., et al. (2022) · eBioMedicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 17